Medpace

Historical price data

Medpace is a global CRO with over 30 years of experience providing end-to-end clinical development services from Phase I through IV trials. The company differentiates itself through its full-service integrated model, combining CRO services with wholly-owned central laboratories, bioanalytical labs, imaging core labs, and Phase I units. With approximately 6,200 employees across 46 countries and 32 offices, Medpace serves as an extension of clients' teams, with 90% of their clients being small to mid-size biotechnology companies. The company emphasizes therapeutic expertise, team continuity, and quality execution to accelerate drug development timelines.

Medpace operates a full-service integrated CRO model combining clinical development services with wholly-owned central laboratories, bioanalytical labs, imaging core labs, ECG facilities, and Phase I units. Their proprietary Clinical Trial Management System integrates all study data on a single platform for enhanced efficiency and productivity.

74 drugs in pipeline, 23 in Phase 3

Total raised: $150M

Medpace competes with major CROs like IQVIA, Syneos Health, and PPD but differentiates through its integrated full-service model, biotech focus, and organic growth strategy. The company's therapeutic specialization and team continuity approach provides competitive advantages versus larger, acquisition-driven competitors.